150 related articles for article (PubMed ID: 10445424)
21. Endometrial cancer after tamoxifen treatment of breast cancer. Results of a retrospective cohort study.
Vrscaj MU; Bebar S; Djurisic A; Fras PA
Eur J Gynaecol Oncol; 1999; 20(1):20-5. PubMed ID: 10422675
[TBL] [Abstract][Full Text] [Related]
22. Re: second cancers after adjuvant tamoxifen therapy for breast cancer.
Rutqvist LE
J Natl Cancer Inst; 1996 Oct; 88(20):1497-9; author reply, 1497-9. PubMed ID: 8841030
[No Abstract] [Full Text] [Related]
23. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen.
Fung MF; Reid A; Faught W; Le T; Chenier C; Verma S; Brydon E; Fung KF
Gynecol Oncol; 2003 Oct; 91(1):154-9. PubMed ID: 14529676
[TBL] [Abstract][Full Text] [Related]
24. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
Hoogendoorn WE; Hollema H; van Boven HH; Bergman E; de Leeuw-Mantel G; Platteel I; Fles R; Nederlof PM; Mourits MJ; van Leeuwen FE;
Breast Cancer Res Treat; 2008 Nov; 112(1):99-108. PubMed ID: 18064567
[TBL] [Abstract][Full Text] [Related]
25. [Adjuvant therapy of breast cancer with tamoxifen and endometrial carcinoma].
Mignotte H; Sasco AJ; Lasset C; Saez S; Rivoire M; Bobin JY
Bull Cancer; 1992; 79(10):969-77. PubMed ID: 1292764
[TBL] [Abstract][Full Text] [Related]
26. Iatrogenic endometrial megapolyps in women with breast carcinoma.
Berezowsky J; Chalvardjian A; Murray D
Obstet Gynecol; 1994 Oct; 84(4 Pt 2):727-30. PubMed ID: 9205466
[TBL] [Abstract][Full Text] [Related]
27. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use.
Cuenca RE; Giachino J; Arredondo MA; Hempling R; Edge SB
Cancer; 1996 May; 77(10):2058-63. PubMed ID: 8640670
[TBL] [Abstract][Full Text] [Related]
28. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
29. Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.
Love RR
J Natl Cancer Inst; 1994 Jul; 86(13):1025-6. PubMed ID: 8007012
[No Abstract] [Full Text] [Related]
30. Uterine malignancy following tamoxifen use in breast cancer patients in Iran: case series and literature review.
Behtash N; Hashemi R; Karimi Zarchi M
Asian Pac J Cancer Prev; 2009; 10(1):163-6. PubMed ID: 19469647
[TBL] [Abstract][Full Text] [Related]
31. Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radiotherapy.
Sasco AJ; Chaplain G; Amoros E; Saez S
Epidemiology; 1996 Jan; 7(1):9-13. PubMed ID: 8664408
[TBL] [Abstract][Full Text] [Related]
32. Effects of tamoxifen on the cervix and uterus in women with breast cancer: experience with Iranian patients and a literature review.
Karimi Zarchi M; Behtash N; Sekhavat L; Dehghan A
Asian Pac J Cancer Prev; 2009; 10(4):595-8. PubMed ID: 19827876
[TBL] [Abstract][Full Text] [Related]
33. Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer.
Rieck GC; Freites ON; Williams S
J Obstet Gynaecol; 2005 Jan; 25(1):39-41. PubMed ID: 16147692
[TBL] [Abstract][Full Text] [Related]
34. Tamoxifen therapy for breast cancer and endometrial cancer risk.
Bernstein L; Deapen D; Cerhan JR; Schwartz SM; Liff J; McGann-Maloney E; Perlman JA; Ford L
J Natl Cancer Inst; 1999 Oct; 91(19):1654-62. PubMed ID: 10511593
[TBL] [Abstract][Full Text] [Related]
35. Tamoxifen and the risk of endometrial cancer in Japanese women with breast cancer.
Yamazawa K; Miyazawa Y; Suzuki M; Wakabayashi M; Kaku H; Matsui H; Sekiya S
Surg Today; 2006; 36(1):41-6. PubMed ID: 16378192
[TBL] [Abstract][Full Text] [Related]
36. The risk of developing uterine sarcoma after tamoxifen use.
Lavie O; Barnett-Griness O; Narod SA; Rennert G
Int J Gynecol Cancer; 2008; 18(2):352-6. PubMed ID: 18334013
[TBL] [Abstract][Full Text] [Related]
37. Role of cyclins A and E in endometrial carcinogenesis in breast cancer patients under tamoxifen treatment.
Metwally AM; Refaat LA; Shaaban H; Megm S; Emara M; Tohamy AA; Sinna EA; Khaled H
J Egypt Natl Canc Inst; 2013 Dec; 25(4):193-8. PubMed ID: 24207091
[TBL] [Abstract][Full Text] [Related]
38. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
[TBL] [Abstract][Full Text] [Related]
39. Risk of endometrial cancer after tamoxifen treatment of breast cancer.
van Leeuwen FE; Benraadt J; Coebergh JW; Kiemeney LA; Gimbrère CH; Otter R; Schouten LJ; Damhuis RA; Bontenbal M; Diepenhorst FW
Lancet; 1994 Feb; 343(8895):448-52. PubMed ID: 7905955
[TBL] [Abstract][Full Text] [Related]
40. Hysteroscopic follow-up in tamoxifen treatment for breast cancer.
Litta P; Azzena A; Sandri A; Vasile C
Clin Exp Obstet Gynecol; 1995; 22(1):47-51. PubMed ID: 7736642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
